POSC251 A Comparison of the Reimbursement of Digital Therapeutics in France, Germany and the UK

The aim of this study was to compare health technology assessment and reimbursement digital therapeutics in France, Germany the UK. Digital (DTx) are rarely differentiated from other technologies (DHTs) such as telemedicine connected care. Submissions NICE, CNEDiMTS BfArM DiGA directories were searched systematically identify DHTs. Interventions classified DTx based on Therapeutics Alliance definition. In DHTs assessed by CNEDiMTS, using same process for all medical devices. Most monitored cardiovascular conditions implantable devices (89%). Of those that met definition (2%), concluded one intervention had insufficient evidence, provided moderate additional benefit minor benefit. May 2020, introduced a specific DHTs, via BfArM. assessments completed, 30% achieved reimbursement, 7% negative outcome 63% applications withdrawn. All reimbursed products definition; most psychiatry interventions (53%). 29% permanent listing directory demonstrated an improvement status. NICE established pilot project assessing UK; Zio XT first product framework. Assessments 2 currently progress (Sleepio myCOPD). A targeted search also identified advice (a form evidence summary rather than formal assessment) 14 DTx. has DTx, reflecting alignment between BfArM’s criteria products. France very few is less well defined or Germany. routes these two countries expected evolve become more distinct common.